MiNK Initiates Randomized Phase 2 Trial for agenT-797 in ARDS

What happened

MiNK Therapeutics announced on its Q3 earnings call that it has initiated a randomized Phase 2 trial of its lead iNKT cell therapy, agenT-797, in patients with severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026. This represents a meaningful advance from the prior plan to seek external funding or collaborations for the viral ARDS program, indicating that the company has moved forward with internal execution. The trial adds a near-term clinical catalyst beyond the oncology-focused efforts and the planned MiNK-215 IND, potentially broadening the value proposition. However, the company's balance sheet remains constrained, with roughly $17.6 million in cash following the July 2025 ATM raise and a going-concern disclosure, so funding the trial will intensify cash burn. Investors should view this as a positive step in derisking the ARDS pathway but must weigh it against the heightened capital requirements and the long timeline to data.

Implication

For investors, the initiation of a randomized Phase 2 for agenT-797 in ARDS removes a layer of uncertainty around the program's advancement, shifting it from a potential collaboration to an active internal asset. However, the company's limited cash runway likely means that additional financing will be needed before the 2026 data readout, which could lead to dilution or unfavorable terms. Near-term focus should remain on the MiNK-215 IND submission and any updates on the oncology front, as those catalysts may occur sooner and have clearer defined endpoints. While the ARDS program now has a near-term milestone, the expected data is more than a year away, and clinical success is far from guaranteed given the mixed history of cell therapies in inflammatory conditions. Therefore, we maintain a HOLD/NEUTRAL stance, awaiting further clarity on financing and early clinical signals, with a bias to upgrade if additional funding is secured on reasonable terms or if early ARDS data looks promising.

Thesis delta

The previous thesis considered the ARDS program as externally dependent, with advancement contingent on securing partnerships or non-dilutive funding. With the initiation of a randomized Phase 2, that dependency is removed, suggesting greater internal commitment and execution capability. Nevertheless, this likely accelerates cash consumption, reinforcing the going-concern risk and the need for near-term capital; thus, the overall stance remains HOLD, with positive ARDS data or favorable financing as potential triggers for an upgrade.